Heinz Gisslinger, MD, Medical University of Vienna, discusses the phase III PROUD-PV study, which evaluated ropeginterferon alfa-2b (P1101) for the treatment of polycythemia vera (PV) during the American Society of Hematology (ASH) Annual Meeting.
The starting point of the study was to compare the new compound ropeginterferon alfa-2b with hydroxyurea (Hydrea), Gisslinger says. Interferons are very slow acting compounds, so the full strength of the compound will not be seen during the first year of treatment.
In the comparison study, ropeginterferon alfa-2b was found to be non-inferior to hydroxyurea with regard to efficacy. However, ropeginterferon alfa-2b was found to be superior in its total ability in comparison to hydroxyurea, which was a surprise, Gisslinger says.
<<< View more from the 2016 ASH Annual Meeting